癌ヤーヌスキナーゼ阻害剤の世界市場機会・治験インサイト

◆英語タイトル:Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023
◆商品コード:KUIK80308
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2017年10月
◆ページ数:190
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD3,300 ⇒換算¥363,000見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥528,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Kuick Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer janus kinase inhibitor market. As per report findings, janus kinase inhibitors have emerged as one of the new potential candidate and growth frontier for the various stake holders involved in the research and development of cancer drugs and therapies. At present there is only one janus kinase inhibitors based drug commercially available in the market and 27 drugs are in the various clinical development phases. Most of the drugs are in Preclinical phase (13 Drugs) followed by the Phase-II ( 4 Drugs) clinical trials.
“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” Highlights:

• Mechanism of Action of JAK/STAT Inhibitors
• Global Cancer JAK/STAT Inhibitor Market Outlook
• Global JAK/STAT Inhibitor Market Opportunity: US$ 4 Billion
• Global JAK/STAT Inhibitor in Pipeline: 27 Drugs
• Global Cancer JAK/STAT Inhibitor Therapy Price Analysis
• Global Cancer JAK/STAT Inhibitor Market Dynamics
• Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company & Phase
• Marketed Cancer Janus Kinase Inhibitors Clinical Insight
• Comparative Price Analysis of JAK/STAT Inhibitors & Conventional Cancer Therapies

The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.

JAK/STAT inhibitor being the latest invention in the field of targeted therapies is considered as the best available therapy for cancer by many scientific researchers. JAK/STAT inhibitors target the process involved in the production of the damaged DNA which is playing the major role in developing cancerous cells. The available JAK/STAT inhibitors are highly focused on treating the rare hematological malignancies like myelofibrosis, polycythemia Vera and primary thrombocythemia. However, the continuous efforts of the research community has led to the identification of the role of JAK/STAT pathway in a wide range of tumors including solid tumors like lung cancer, pancreatic cancer, prostate cancer, breast cancer, colorectal cancer, ovarian cancer, gastrointestinal cancers etc.

The global revenue collection from currently available JAK/STAT inhibitor drug; Ruxolitinib, has been very impressive since its approval. Although the drug is approved for treating rare hematological malignancies but incidence rate of these cancers has been found to be increasing in the past five years. Furthermore, the lack of effective treatment for such cancers and increased survival rates of the patients after getting a treatment with Ruxolitinib has aided the commercial success of Ruxolitinib.

More than 5 JAK/STAT inhibitors are expected to enter the cancer therapeutic market in the next decade. The development of JAK/STAT inhibitors has been so impressive and rapid in the past five years that a great economic success of this class of drugs is expected in the nearby future. Additionally, huge commercial success of the JAK inhibitor Ruxolitinib for myeloproliferative disorders has further accelerated the development of more JAK/STAT inhibitors. Advancements in research and technology will aid the development of JAK/STAT inhibitors. The development of more JAK/STAT inhibitors will not only provide benefits to the cancer therapeutic market but will also provide a better life to the patients suffering from cancers.

Past success of JAK/STAT inhibitors has provided an overview of its future market. The clinical success of JAK inhibitor, Ruxolitinib has gained adequate popularity among the patients and the physicians. Due to this reason, the demand of JAK/STAT inhibitors is highly increased. Furthermore, the popularity of Ruxolitinib will aid the market success of other JAK/STAT inhibitory drugs which are going to be licensed very soon.

【レポートの目次】

1. Prologue to JAK/STAT Pathway
1.1 Overview
1.2 Categorization of JAK/STAT Inhibitors in Cancer Therapeutics

2. Role of JAK/STAT Pathway in Tumor Formation

3. JAK/STAT Inhibitors: Modern Therapeutics for Effective Cancer Management

4. Understanding the Targets for Inhibition: An Insight into JAK & STAT Proteins
4.1 Structure & Significance
4.1.1 Janus Kinases: A Novel Cytokine Receptor
4.1.2 STAT Proteins: The Signal Generators for Transcription
4.2 Importance of Modulation of JAK/STAT in a Healthy Cell

5. Mechanism of Action of JAK/STAT Inhibitors

6. Identification of Active Target in Tumor Cells for JAK/STAT Inhibition
6.1 Cell Based Assays
6.2 Biochemical Assays

7. Need & Superiority of JAK/STAT Inhibitors: Its Importance in Modern Cancer Therapy

8. JAK/STAT Inhibitors in Cancer Therapy
8.1 Hematological Malignancies
8.1.1 Myelofibrosis
8.1.2 Acute Lymphoblastic Leukemia
8.1.3 Polycythemia Vera
8.1.4 Primary thrombocythemia
8.2 Solid Tumors
8.2.1 Lung Cancer
8.2.2 Ovarian Cancer
8.2.3 Breast Cancer
8.2.4 Pancreatic Cancer
8.2.5 Hepatocellular Carcinoma
8.2.6 Colorectal cancer
8.2.7 Head & Neck Squamous Cell Carcinoma
8.2.8 Prostate Cancer
8.2.9 Glioblastoma
8.2.10 Other Solid Tumors

9. Cancer JAK/STAT Inhibitor Drugs
9.1 Approved Drugs
9.1.1 Ruxolitinib
9.2 Promising Candidates in the Clinical Pipeline
9.2.1 Momelotinib
9.2.2 Lestaurtinib
9.2.3 Pacritinib

10. Global Cancer JAK/STAT Inhibitor Market Outlook
10.1 Current Scenario
10.2 Clinical Pipeline Overview

11. Global Cancer JAK/STAT Inhibitor Therapy Price Analysis
11.1 Analyzing the Cost of Available JAK/STAT Inhibitor
11.2 Comparative Price Analysis of JAK/STAT Inhibitors and Best Available Therapy
11.3 Comparative Price Analysis of JAK/STAT Inhibitors & Conventional Cancer Therapies
11.4 Comparative Price Analysis of JAK/STAT Inhibitors & Newly Approved Anti-Cancer Therapeutics

12. Global Cancer JAK/STAT Inhibitor Market Dynamics
12.1 Favorable Factors for Cancer JAK/STAT Inhibitors Market
12.1.1 Elevation in Disease Burden
12.1.2 Unmet Medical Need
12.1.3 Advancement in Technology
12.1.4 Strong Clinical Pipeline
12.1.5 Orphan Drug Status to JAK/STAT Inhibitors
12.1.6 Commercial Success of Ruxolitinib
12.2 Market challenges for Cancer JAK/STAT Inhibitors
12.2.1 Scientific Limitations and the Number of Side Effects
12.2.2 Clinical Hold on Pacritinib
12.2.3 Tedious approval process

13. Global Cancer JAK/STAT Inhibitor Market Future Outlook

14. Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company & Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-III
14.7 Preregistration

15. Marketed Cancer Janus Kinase Inhibitors Clinical Insight by Company
15.1 Ruxolitinib (Jakafi & Jakavi)

16. Suspended Cancer Janus Kinase Inhibitors in Clinical Pipeline by Company & Phase
16.1 No Development Reported
16.2 Discontinued

17. Competitive Landscape
17.1 Abbott Laboratories
17.2 Asana Biosciences
17.3 Astra Zeneca
17.4 Celon Pharmaceuticals
17.5 Dynamic Pharma
17.6 Eli Lilly
17.7 Gilead Sciences
17.8 Hanmi Pharmaceuticals
17.9 Incyte
17.10 Kyowa Hakko
17.11 Moleculin
17.12 Pfizer
17.13 PIQUR Therapeutics
17.14 Portola Pharmaceuticals
17.15 S*BIO

Figure 1-1: Conventional Approaches for Treating Cancer
Figure 1-2: Major Limitations of Conventional Cancer Therapies
Figure 1-3: Modern Approach in Cancer Therapy
Figure 1-4: Major Types of Cancer Treatment Modalities
Figure 1-5: Categorization of JAK Inhibitors in Targeted Therapies
Figure 3-1: Advanced Approaches for the Development of JAK/STAT Inhibitors
Figure 4-1: Architecture of the Structure of Janus Kinase
Figure 4-2: Cis Mode of Activation of Janus Kinase
Figure 4-3: Trans Mode of Activation of Janus Kinase
Figure 4-4: Architecture of the Structure of STAT Proteins
Figure 4-5: Activation of STAT Proteins
Figure 4-6: Natural Inhibitors of JAK/STAT Signaling Pathway
Figure 5-1: JAK/STAT Signaling Pathway in Normal Human Cell
Figure 5-2: JAK/STAT Pathway in Hematological Cancers
Figure 5-3: Mechanism of Action of JAK inhibitors
Figure 6-1: Technologies Used For Diagnosing JAK/STAT Pathway in Tumor Cells
Figure 7-1: Advanced Features of JAK/STAT Inhibitors in Cancer Therapy
Figure 8-1: JAK/STAT Mutations in Hematological Malignancies
Figure 9-1: Target & Effects of Ruxolitinib
Figure 9-2: Impact of Ruxolitinib on Change in Mean Spleen Size
Figure 10-1: Global Prevalence - Myelofibrosis Patients (Numbers), 2015-17
Figure 10-2: Global Prevalence - Polycythemia Vera Patients (Numbers), 2015-17
Figure 10-3 Global Prevalence - Primary Thrombocythemia Patients (Numbers), 2015-17
Figure 10-4 : Global- Ruxolitinib Revenue for Myelofibrosis (US$ Million), 2015-2017
Figure 10-5: Global - Ruxolitinib Revenue for Polycythemia Vera (US$ Million), 2015-2017
Figure 10-6: Global- Ruxolitinib Revenue for Primary Thrombocythemia (US$ Million), 2015-2017
Figure 10-7: Global- Ruxolitinib Revenue by Hematological Malignancies (%), 2016
Figure 10-8: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023
Figure 10-9: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 10-10: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023
Figure 10-11: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 11-1: Ruxolitinib – Average Per Tablet & Packet Cost Analysis (US$)
Figure 11-2: Ruxolitinib – Average & Lifetime Treatment Cost Analysis (US$)
Figure 11-3: Global- Average Price of Ruxolitinib Treatment (US$/Month), 2015-2017
Figure 11-4: Survival Rate of Myelofibrosis Patients Undergoing Ruxolitinib Treatment v/s Best Available Therapy
Figure 11-5: Global - Average Lifetime Expenditure of Myelofibrosis Patient (US$)
Figure 11-6: Global - Average Lifetime Drug & Resource Cost (US$)
Figure 11-7: Global - Average Cost of Complete Treatment of Myelofibrosis Patient (US$)
Figure 11-8: Quality Adjusted Life Years for Ruxolitinib & Best Available Therapy for Myelofibrosis
Figure 11-9: Average Cost of JAK/STAT Inhibitors & Conventional Therapies for Cancer (US$/Month)
Figure 11-10: Complete Treatment Cost of JAK/STAT Inhibitors & Monoclonal Antibody Drug (US$)
Figure 11-11: Treatment Cost of JAK/STAT Inhibitors & CAR-T Cell Therapy for Cancer (US$)
Figure 11-12: Treatment Cost of JAK/STAT Inhibitors & Other Small Molecule Cancer Drugs (US$)
Figure 12-1: Global – Cancer JAK/STAT Inhibitor Market Drivers
Figure 12-2: Global - Challenges for Cancer JAK/STAT Inhibitors Market
Figure 13-1: Global- Cancer JAK/STAT Inhibitors Market Opportunity (US$ Billion), 2018-2023



Table 2-1: JAK Mutations in Cancers
Table 2-2: STAT Mutations in Cancers
Table 11-1: Ruxolitinib Price Analysis


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 癌ヤーヌスキナーゼ阻害剤の世界市場機会・治験インサイト(Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆